Boston, MA 02\/20\/2014 (wallstreetpr) –\u00a0Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)<\/b>: According to the latest 13F filings, Sarissa Capital managed by Alex Denner revealed holding about 12 million shares of ARIA common stock. Given that amount of common stock ownership, the hedge fund\u2019s stake in the biotech company is roughly 6.2 percent. Mr. Denner has expansive understanding of healthcare stocks. He previously served as healthcare and biotechnology portfolio funds manager at Morgan Stanley (NYSE:MS). That Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)\u2019s latest leukemia drug Iclusig has been given market authorization in the U.S. and several other global markets is perhaps one of the reasons institutional and everyday investors are jostling for a position in ARIA. The stock lost 2.16 percent of its market value in the last session to close at $8.60.<\/p>\n
Morgan Stanley (NYSE:MS)<\/b> boss has disclosed in regulatory filing with the U.S. Securities and Exchange Commission that he donated shares worth $1 million, that is roughly 30,000 shares. It is reported that the shares were given away last week, yet details are lacking about where the shares went. MS chief James Gorman directly owns over a million shares of Morgan Stanley. The executive used his own money to acquire about 100,000 shares of MS in 2011, at the cost of $20, in a show of confidence in the stock\u2019s future at a time when investor confidence was waning. By end of January when shares of Morgan Stanley (NYSE:MS) breached $29, Mr. Gorman had netted roughly $1 million on paper. Shares of Morgan Stanley (NYSE:MS) settled around $28.96, having gained more than 2 percent in the last session.<\/p>\n
Yamana Gold Inc. (USA) (NYSE:AUY)<\/b> was in tatters on NYSE after the company reported unexpected loss for the fourth quarter. AUY blamed its latest woe on after-tax impairment cost from various exploration and production properties. The impact was due to drop in metal prices. It was also a quarter that was characterized by low sales volumes and high cash costs. The company lost $583.9 million, translating to 78 cents per share for the quarter ending December. That compared with profit of $169.2 million, translating to 23 cents per share, realized in the same period a year ago. The adjusted figures of Yamana Gold Inc. (USA) (NYSE:AUY)\u2019s earnings resulted in 5 cents EPS, while analysts were expecting 7 cents per share.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/20\/2014 (wallstreetpr) –\u00a0Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): According to the latest 13F filings, Sarissa Capital managed by Alex Denner revealed holding about 12 million […]<\/p>\n","protected":false},"author":13,"featured_media":15648,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1942],"tags":[2780,1877,2781,4540,1431,4539],"stock_ticker":[],"class_list":["post-15647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-banking","tag-ariad-pharmaceuticals-inc-nasdaqaria","tag-morgan-stanley-nysems","tag-nasdaqaria","tag-nyseauy","tag-nysems","tag-yamana-gold-inc-usa-nyseauy","entry"],"acf":[],"yoast_head":"\n